Cell-surface D-galactose-containing glycans

Cell-surface D-galactose-containing glycans are a diverse class of carbohydrate structures found on the plasma membrane of various cell types, characterized by terminal D-galactose or N-acetylgalactosamine (GalNAc) residues. These glycans serve as essential recognition motifs for endogenous receptors such as the asialoglycoprotein receptor (ASGPR) on hepatocytes and the galectin family of proteins, playing key roles in protein clearance, cell adhesion, and immune signaling (D'Souza & Devarajan, 2015; Johannes et al., 2018). In pathological contexts, particularly in oncology, the overexpression or altered branching of these glycans, such as the Thomsen-Friedenreich (TF) antigen, contributes to tumor metastasis, immune evasion, and poor prognosis (Heimburg-Molinaro et al., 2011). Therapeutic strategies involving these glycans include the use of lectins and monoclonal antibodies to directly target cancer cells, as well as the exploitation of these motifs as targeting ligands in GalNAc-conjugated oligonucleotide therapies for liver-specific drug delivery (Alnylam Pharmaceuticals, 2023). Understanding the spatial distribution and density of these glycans is crucial for optimizing the efficacy and safety of glycan-targeted interventions.

Other names

Terminal galactose-containing glycansAsialoglycansGalactose-terminated glycoconjugatesBeta-galactoside-containing glycansGalactose-containing cell-surface glycans

Drugs targeting these glycans typically function by binding to terminal galactose or GalNAc residues to induce cell death (e.g., ribosome-inactivating lectins), block cell-cell interactions (e.g., monoclonal antibodies), or facilitate the targeted delivery of therapeutic payloads via receptor-mediated endocytosis (e.g., ASGPR-mediated uptake of GalNAc-conjugates).